Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLC

Recruiting

• Conditions: lung cancer; Non-small-cell lung carcinoma; 10038666

• Registration Number: NL-OMON48625
• Lead Sponsor: Jeroen Bosch Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 150

Inclusion Criteria

Patients with NSCLC (initial diagnosis and progressive disease) that are eligible for KRAS/EGFR mutation analysis on tissue biopsy as performed for standard of care.

Exclusion Criteria

Patients with NSCLC where tissue biopsy was not successful.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The agreement between liquid biopsy and tissue biopsy based KRAS/EGFR molecular<br /><br>diagnostics that will be determined using Contigency table analysis and<br /><br>comparison of parameters such as specificity, sensitivity, positive and<br /><br>negative predictive values and Cohen*s kappa coefficient.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>